Investors Relieved As Mylan Settlement Avoids Investigation
Executive Summary
Mylan shares rallied on Oct. 7 following the company’s late-day Oct. 10 announcement that it agreed to settlement terms with the Department of Justice related to Epipen rebates for Medicaid prescriptions, but separate investigations and competition are looming.
You may also be interested in...
The End Is Nigh For Mylan, But How Different Will The New Company Be?
Mylan will be merged into a new company with Pfizer’s Upjohn, closing the chapter on a generic drug powerhouse that will be remembered as much for scandal as success.
You Work In The Pharmaceutical Industry; Here's Why You Should Care About The Novartis Payments
There's a lot of finger-pointing in the industry when it comes to why pharma has a bad reputation. Maybe it's time everyone who works in pharmaceuticals takes responsibility for it.
You Work In The Pharmaceutical Industry; Here's Why You Should Care About The Novartis Payments
There's a lot of finger-pointing in the industry when it comes to why pharma has a bad reputation. Maybe it's time everyone who works in pharmaceuticals takes responsibility for it.